A Science Immunology Review explains how memory B cells acquire diverse molecular, epigenetic, and tissue-specific programs ...
TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell ...
Tvardi Therapeutics (Nasdaq: TVRD) shares surge after Phase 1 results show TTI-109 matched TTI-101's exposure with better tolerability and clear STAT3 target engagement.
Tooth enamel is the hardest substance in the human body, yet once damaged, it cannot regenerate naturally. To overcome this ...
WHO-origin Master and Working Cell Banks provide vaccine developers with a ready-to-use Vero cell substrate for licensing, purchase, and integrated CDMO programsQualified Vero Master Cell Bank and Wor ...
To prevent viruses from sickening or killing us—whether it's an individual case of hepatitis B or a COVID pandemic—it's ...
First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into ...
ASCO 2026 highlighted a shift toward precision-driven oncology R&D, where biomarkers, ctDNA, and integrated strategies guide ...
New research is shedding light on the biological mechanisms that may help explain why systemic lupus erthyematosus (SLE) and ...
A growing body of research suggests that endometriosis may arise from more than retrograde menstruation alone. Investigators ...
Traditional therapeutics target the inactive conformation of proteins, allowing tumors to adapt and resume signaling.
The FDA provided favorable feedback on NewcelX’s Chemistry, Manufacturing, and Controls (“CMC”) processes and preclinical program allowing the Company to proceed toward its Investigational New Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results